尽管COVID-19遭到破坏，但由于后期管道测试“步入正轨”，罗

StephenW

Roche drops hep B antiviral as late-stage pipeline tests'largely on track' despite COVID-19 disruption
by
Ben Adams | Jul 23, 2020 7:45am


Roche has canned a phase 1 test of a potential hepatitis B antiviral as part of its third-quarter clean-up of unwanted pipeline drugs.

In its second-quarter/half-year financials posted Thursday morning, Roche said simply that the drug, RG6217, had been “removed” from phase 1, which in pharma parlance means culled.

It had been in an early clinical trial since late 2018, according to ClinicalTrials.gov, in both healthy volunteers and those with hep B. Roche did not make public the reason for its axing.

The Swiss major also confirmed it had swept out two other duds: FDA breakthrough-tagged autism hopeful balovaptan (RG7314) and idasanutlin (RG7388), an investigational MDM2 inhibitor being tested for relapsed or refractory acute myeloid leukemia in phase 3.

The company confirmed their removal from its pipeline after noting they were on the chopping block back in the first quarter.

Roche booked just a 1% rise in sales for the first half of the year, given what it called a “significant impact” from COVID-19. It said in its financial report (PDF) that while the virus had affected some of its trial work, “filings, pivotal phase 3 trial readouts and pivotal trial starts are largely on track.”

It’s also working on “several new compounds” for their potential against COVID-19 as well as six other approved meds it thinks could help against the disease.

StephenW

尽管COVID-19遭到破坏，但由于后期管道测试“步入正轨”，罗氏仍放弃了乙肝抗病毒药物
通过
本·亚当斯| 2020年7月23日上午7:45


罗氏（Roche）已取消对潜在的乙型肝炎病毒的第一阶段测试，作为其第三季度清理不需要的管道药物的一部分。

罗氏在周四上午发布的第二季度/半年度财务报告中仅表示，RG6217药物已从第一阶段“移出”，在医药界看来是被淘汰。

根据ClinicalTrials.gov的说法，自2018年底以来，它一直在健康志愿者和乙型肝炎患者中进行早期临床试验。罗氏并未公开其致死原因。

这名瑞士大学生还证实，它已经扫除了另外两个笨蛋：FDA突破性的自闭症患者希望的巴洛伐坦（RG7314）和伊达沙那林（RG7388），这是一种正在研究中的MDM2抑制剂，正在接受3期复发或难治性急性髓细胞白血病的测试。

该公司在注意到第一季度他们在砧板上之后，确认将其从管道中移除。

考虑到COVID-19带来的“重大影响”，罗氏上半年的销售额仅增长了1％。它在其财务报告（PDF）中表示，尽管该病毒影响了其某些试验工作，但“归档，关键的3期试验读数和关键的试验开始已步入正轨。”

它还正在研究“几种新化合物”，因为它们具有抗COVID-19的潜力以及其他六种已批准的药物，它们可能有助于抵抗这种疾病。